Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243


Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer.

Baquero MT, Hanna JA, Neumeister V, Cheng H, Molinaro AM, Harris LN, Rimm DL.

Cancer. 2012 Oct 1;118(19):4660-9. doi: 10.1002/cncr.27453. Epub 2012 Feb 22.


Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts.

Baquero MT, Lostritto K, Gustavson MD, Bassi KA, Appia F, Camp RL, Molinaro AM, Harris LN, Rimm DL.

Breast Cancer Res. 2011 Nov 2;13(5):R85. doi: 10.1186/bcr2937.


Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.


Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer.

Won HS, Lee KE, Sung SH, Choi MY, Jo JY, Nam EM, Mun YC, Seong CM, Lee SN.

Tumori. 2014 Jan-Feb;100(1):80-6. doi: 10.1700/1430.15820.


Expression of S100A4 and Met: potential predictors for metastasis and survival in early-stage breast cancer.

Lee WY, Su WC, Lin PW, Guo HR, Chang TW, Chen HH.

Oncology. 2004;66(6):429-38.


Grb14 as an independent good prognosis factor for breast cancer patients treated with neoadjuvant chemotherapy.

Huang O, Jiang M, Zhang X, Xie Z, Chen X, Wu J, Liu H, Shen K.

Jpn J Clin Oncol. 2013 Nov;43(11):1064-72. doi: 10.1093/jjco/hyt130. Epub 2013 Sep 12.


Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.

Wosnitzer MS, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack DP, Benson MC, McKiernan JM, Cordon-Cardo C.

J Urol. 2011 Nov;186(5):2094-100. doi: 10.1016/j.juro.2011.06.051. Epub 2011 Sep 23.


Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer.

Cao YW, Li WQ, Wan GX, Li YX, Du XM, Li YC, Li F.

J Exp Clin Cancer Res. 2014 Nov 25;33:97. doi: 10.1186/s13046-014-0097-2.


Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM.

BMC Cancer. 2010 Nov 23;10:639. doi: 10.1186/1471-2407-10-639.


Increased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expression.

Alford SH, Toy K, Merajver SD, Kleer CG.

Breast Cancer Res Treat. 2012 Apr;132(2):429-37. doi: 10.1007/s10549-011-1591-2. Epub 2011 May 26.


Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial.

Pusztai L, Jeong JH, Gong Y, Ross JS, Kim C, Paik S, Rouzier R, Andre F, Hortobagyi GN, Wolmark N, Symmans WF.

J Clin Oncol. 2009 Sep 10;27(26):4287-92. doi: 10.1200/JCO.2008.21.6887. Epub 2009 Aug 10.


Overexpression of TNFAIP8 is associated with tumor aggressiveness and poor prognosis in patients with invasive ductal breast carcinoma.

Xiao M, Xu Q, Lou C, Qin Y, Ning X, Liu T, Zhao X, Jia S, Huang Y.

Hum Pathol. 2017 Apr;62:40-49. doi: 10.1016/j.humpath.2016.12.020. Epub 2017 Jan 10.


Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ.

Cancer. 2014 Jul 1;120(13):1932-8. doi: 10.1002/cncr.28689. Epub 2014 Mar 26.


A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C.

J Pathol. 2012 Jan;226(1):97-107. doi: 10.1002/path.2976. Epub 2011 Sep 26.


Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer.

Nadler Y, Camp RL, Giltnane JM, Moeder C, Rimm DL, Kluger HM, Kluger Y.

Breast Cancer Res. 2008;10(2):R35. doi: 10.1186/bcr1998. Epub 2008 Apr 23.


Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer.

O Leary PC, Penny SA, Dolan RT, Kelly CM, Madden SF, Rexhepaj E, Brennan DJ, McCann AH, Pontén F, Uhlén M, Zagozdzon R, Duffy MJ, Kell MR, Jirström K, Gallagher WM.

BMC Cancer. 2013 Apr 2;13:175. doi: 10.1186/1471-2407-13-175.


Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Carvajal-Hausdorf DE, Schalper KA, Pusztai L, Psyrri A, Kalogeras KT, Kotoula V, Fountzilas G, Rimm DL.

J Natl Cancer Inst. 2015 May 19;107(8). pii: djv136. doi: 10.1093/jnci/djv136. Print 2015 Aug.


Up-regulation of cell cycle arrest protein BTG2 correlates with increased overall survival in breast cancer, as detected by immunohistochemistry using tissue microarray.

Möllerström E, Kovács A, Lövgren K, Nemes S, Delle U, Danielsson A, Parris T, Brennan DJ, Jirström K, Karlsson P, Helou K.

BMC Cancer. 2010 Jun 16;10:296. doi: 10.1186/1471-2407-10-296.


CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.

Dietrich D, Krispin M, Dietrich J, Fassbender A, Lewin J, Harbeck N, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Spyratos F, Foekens JA, Lesche R, Martens JW.

BMC Cancer. 2010 Jun 1;10:247. doi: 10.1186/1471-2407-10-247.


TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients.

Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R.

BMC Cancer. 2015 Jun 4;15:453. doi: 10.1186/s12885-015-1471-y.

Supplemental Content

Support Center